image
Healthcare - Biotechnology - NASDAQ - US
$ 4.39
-4.77 %
$ 37.9 M
Market Cap
-0.37
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one KPTI stock under the worst case scenario is HIDDEN Compared to the current market price of 4.39 USD, Karyopharm Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one KPTI stock under the base case scenario is HIDDEN Compared to the current market price of 4.39 USD, Karyopharm Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one KPTI stock under the best case scenario is HIDDEN Compared to the current market price of 4.39 USD, Karyopharm Therapeutics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart KPTI

image
$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
145 M REVENUE
-0.55%
-119 M OPERATING INCOME
7.79%
-76.4 M NET INCOME
46.60%
-127 M OPERATING CASH FLOW
-37.49%
95.5 M INVESTING CASH FLOW
1102.43%
41.6 M FINANCING CASH FLOW
3605.16%
30 M REVENUE
-1.73%
-33.3 M OPERATING INCOME
-6.31%
-23.5 M NET INCOME
23.78%
-39 M OPERATING CASH FLOW
-51.04%
15.3 M INVESTING CASH FLOW
3.32%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Karyopharm Therapeutics Inc.
image
Current Assets 156 M
Cash & Short-Term Investments 109 M
Receivables 30.8 M
Other Current Assets 17 M
Non-Current Assets 7.93 M
Long-Term Investments 0
PP&E 6.28 M
Other Non-Current Assets 1.64 M
66.12 %18.71 %10.35 %3.82 %Total Assets$164.4m
Current Liabilities 92.3 M
Accounts Payable 5.11 M
Short-Term Debt 24.9 M
Other Current Liabilities 62.3 M
Non-Current Liabilities 258 M
Long-Term Debt 170 M
Other Non-Current Liabilities 88.5 M
7.10 %17.78 %48.41 %25.26 %Total Liabilities$350.4m
EFFICIENCY
Earnings Waterfall Karyopharm Therapeutics Inc.
image
Revenue 145 M
Cost Of Revenue 6.01 M
Gross Profit 139 M
Operating Expenses 259 M
Operating Income -119 M
Other Expenses -43 M
Net Income -76.4 M
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)145m(6m)139m(259m)(119m)43m(76m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
95.86% GROSS MARGIN
95.86%
-82.24% OPERATING MARGIN
-82.24%
-52.62% NET MARGIN
-52.62%
41.08% ROE
41.08%
-46.48% ROA
-46.48%
-123.21% ROIC
-123.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Karyopharm Therapeutics Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -76.4 M
Depreciation & Amortization -2.16 M
Capital Expenditures -142 K
Stock-Based Compensation 18.4 M
Change in Working Capital -302 K
Others -69.5 M
Free Cash Flow -128 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Karyopharm Therapeutics Inc.
image
Wall Street analysts predict an average 1-year price target for KPTI of $7.5 , with forecasts ranging from a low of $3 to a high of $14 .
KPTI Lowest Price Target Wall Street Target
3 USD -31.66%
KPTI Average Price Target Wall Street Target
7.5 USD 70.84%
KPTI Highest Price Target Wall Street Target
14 USD 218.91%
Price
Max Price Target
Min Price Target
Average Price Target
161614141212101088664422Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Karyopharm Therapeutics Inc.
image
Sold
0-3 MONTHS
4.27 K USD 2
3-6 MONTHS
28 K USD 3
6-9 MONTHS
9.45 K USD 1
9-12 MONTHS
24 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWTON, Mass. , July 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 666 restricted stock units (RSUs) to two newly-hired employees. prnewswire.com - 1 week ago
Karyopharm to Present at the Jefferies Global Healthcare Conference NEWTON, Mass. , June 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m. prnewswire.com - 1 month ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWTON, Mass. , June 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 566 restricted stock units (RSUs) to two newly-hired employees. prnewswire.com - 1 month ago
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 1 month ago
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 521.6% in Karyopharm Therapeutics (KPTI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 1 month ago
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference NEWTON, Mass. , May 19, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m. prnewswire.com - 1 month ago
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting NEWTON, Mass. , May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. prnewswire.com - 1 month ago
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday. benzinga.com - 1 month ago
Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brendan Strong - Senior Vice President, Investor Relations & Corporate Communications Richard Paulson - President & Chief Executive Officer Reshma Rangwala - Chief Medical Officer & Head, Research Sohanya Cheng - Chief Commercial Officer & Head, Business Development Lori Macomber - Chief Financial Officer & Treasurer Conference Call Participants Colleen Kusy - Baird Ted Tenthoff - Piper Sandler Peter Lawson - Barclays Albert Agustinus - Leerink Partners Operator Good afternoon. My name is Chloe, and I will be your conference operator today. seekingalpha.com - 1 month ago
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.77 per share versus the Zacks Consensus Estimate of a loss of $4.21. This compares to loss of $4.80 per share a year ago. zacks.com - 1 month ago
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification – New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Selinexor's Potential in Combination with Ruxolitinib in JAKi-Naïve Myelofibrosis in Ongoing Phase 3 SENTRY Trial – – Phase 3 SENTRY Trial Passed Planned Futility Analysis; Trial is Approximately 80% Enrolled with Target Enrollment Expected in June/July 2025 – – Demand for XPOVIO® (selinexor) Increased 5% in the First Quarter of 2025 Compared to the First Quarter of 2024; Total Revenue was $30.0 Million; U.S. XPOVIO® Net Product Revenue of $21.1 Million was Adversely Impacted by a $5.0 Million Increase in the Product Return Reserve due to Atypical Returns of Expired 80 mg and 100 mg Units – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Company is Exploring Various Alternatives to Extend Cash Runway – –  Conference Call Scheduled for Today at 4:30 p.m. ET – NEWTON, Mass. prnewswire.com - 1 month ago
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 -- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass. prnewswire.com - 2 months ago
8. Profile Summary

Karyopharm Therapeutics Inc. KPTI

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 37.9 M
Dividend Yield 0.00%
Description Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Contact 85 Wells Avenue, Newton, MA, 02459 https://www.karyopharm.com
IPO Date Nov. 6, 2013
Employees 279
Officers Ms. Kristin Abate Vice President, Chief Accounting Officer & Assistant Treasurer Dr. Mansoor Raza Mirza M.D. Clinical Consultant, Member of Scientific Advisory Board & Independent Director Mr. James Accumanno J.D. Chief Compliance Officer Dr. Reshma Rangwala M.D., Ph.D. Executive Vice President, Chief Medical Officer & Head of Research Ms. Sohanya Cheng M.B.A. Executive Vice President, Chief Commercial Officer & Head of Business Development Dr. Sharon Shacham M.B.A., Ph.D. Co-Founder & Chairman of Scientific Advisory Board Ms. Lori A. Macomber CPA EVice President, Chief Financial Officer & Treasurer Mr. Brendan Twohig Strong SVice President of Investor Relations & Corporate Communications Mr. Michael J. Mano J.D. Senior Vice President, General Counsel & Secretary Mr. Richard A. Paulson M.B.A. President, Chief Executive Officer & Director